Pages that link to "Q42846150"
Jump to navigation
Jump to search
The following pages link to Effects of CYP2C19 genotype on outcomes of clopidogrel treatment (Q42846150):
Displaying 50 items.
- 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (Q22241919) (← links)
- Personalized medicine: hope or hype? (Q24289193) (← links)
- Current status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implications (Q26771106) (← links)
- Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls (Q26775125) (← links)
- The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19 (Q26801867) (← links)
- Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics (Q26822796) (← links)
- Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice? (Q26823542) (← links)
- Antiplatelet and anticoagulation therapy for acute coronary syndromes (Q26824701) (← links)
- The Year in Non–ST-Segment Elevation Acute Coronary Syndrome (Q26829746) (← links)
- Clinical application of cardiovascular pharmacogenetics (Q26849254) (← links)
- Exploring predisposition and treatment response--the promise of genomics (Q26851609) (← links)
- Antiplatelet therapy for carotid artery stenting (Q26852304) (← links)
- The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients (Q26996594) (← links)
- Pharmacogenomics and cardiovascular disease (Q26997380) (← links)
- Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation (Q27011524) (← links)
- Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation? (Q27022443) (← links)
- Towards precision medicine (Q30391847) (← links)
- Quantifying rare, deleterious variation in 12 human cytochrome P450 drug-metabolism genes in a large-scale exome dataset (Q30405778) (← links)
- Genetic susceptibility to ischemic stroke (Q30414709) (← links)
- Dexlansoprazole MR for the management of gastroesophageal reflux disease (Q30453948) (← links)
- Clopidogrel: the data, the experience, and the controversies (Q30573045) (← links)
- Use of genetic data to guide therapy in arterial disease (Q30978916) (← links)
- Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance (Q33365061) (← links)
- Genetic Testing for CYP450 Polymorphisms to Predict Response to Clopidogrel: current evidence and test availabilityApplication: Pharmacogenomics (Q33704998) (← links)
- Antiplatelet agents in acute coronary syndromes. Data from the main clinical trials (Q33794139) (← links)
- Applied pharmacogenomics in cardiovascular medicine (Q33846255) (← links)
- Cytochrome p450 gene variants, race, and mortality among clopidogrel-treated patients after acute myocardial infarction (Q33923341) (← links)
- Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis (Q33982372) (← links)
- Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention. (Q33997642) (← links)
- Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions. (Q34161006) (← links)
- Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial (Q34264876) (← links)
- Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention (Q34419173) (← links)
- Insurance coverage policies for personalized medicine (Q34608654) (← links)
- Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis (Q34624862) (← links)
- CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population (Q34649009) (← links)
- Personalizing health care: feasibility and future implications (Q34938911) (← links)
- Cytochrome P450 2C19*2 polymorphism in patients with stable coronary heart disease and risk for secondary cardiovascular disease events: results of a long-term follow-up study in routine clinical care (Q34975032) (← links)
- Indirect estimation of the comparative treatment effect in pharmacogenomic subgroups (Q34981428) (← links)
- Routine screening for CYP2C19 polymorphisms for patients being treated with clopidogrel is not recommended (Q34990721) (← links)
- Clinical evidence of interaction between clopidogrel and proton pump inhibitors (Q35033722) (← links)
- Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in Chinese patients with percutaneous coronary intervention (Q35122933) (← links)
- The genetics of common variation affecting platelet development, function and pharmaceutical targeting (Q35149898) (← links)
- Genomics and Drug Response (Q35252277) (← links)
- Pharmacogenomics: application to the management of cardiovascular disease (Q35309161) (← links)
- Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations (Q35373683) (← links)
- Cardiovascular pharmacogenomics (Q35447163) (← links)
- CYP2C19 polymorphism and clinical outcomes among patients of different races treated with clopidogrel: A systematic review and meta-analysis (Q35602726) (← links)
- Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy (Q35603072) (← links)
- A surveillance tool to support quality assurance and research in personalized medicine (Q35625171) (← links)
- Recent advances in the diagnosis and treatment of acute myocardial infarction (Q35626702) (← links)